Calif. voters lean toward stem cell measure-pol
By Reuters,
Reuters
| 09. 24. 2004
LOS ANGELES, Sept 23 (Reuters) - A majority of likely voters in California favor a ballot proposal that would authorize $3 billion in state bonds to fund controversial stem cell research, according to a poll released on Thursday.
The referendum, on the Nov. 2 ballot, would create the largest pool of public funding for such research in the United States at a time when the Bush administration has sharply curtailed spending on studies involving embryonic stem cells.
Backers of the initiative, including Hollywood celebrities and Silicon Valley billionaires, argue that such research could potentially lead to cures for diseases such as Parkinson's, Alzheimer's and diabetes.
A survey by the Los Angeles Times showed that while most voters had not yet formed an opinion on the ballot measure known as Proposition 71, a majority expressed support once they were read the proposal itself.
The survey showed 54 percent of likely voters in California said they were inclined to vote for the stem cell proposal, compared with 32 percent who said they would vote against it.
Fourteen percent said they were not...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
